Markets still in a short term downtrend, near the 50 day SMA; sell Delta Corp, Indian Hotels to avoid losses
时间:2024-06-26 08:46:01 阅读(143)
By Subash Gangadharan
On Daily chart, we observe that Nifty is still in a short term downtrend after touching a high of 18,888 in early December 2022. The index is however now near the crucial support of the 50 day SMA. A close below the 50 day SMA at 18144 and the recent lows of 18133 could trigger further weakness that could take the Nifty towards the next support of 17858. On the other hand a bounce back and convincing close above the recent swing highs of 18,473 could bring the bulls back into control. We recommend a wait and watch approach till we see signs of more clarity.
Indian Hotels is in a short term downtrend as it has been making lower tops and lower bottoms for the last few sessions. In the process, it has broken its near term support and seems to have reversed its recent short term uptrend. This indicates that the downtrend looks set to continue. Technical indicators are giving negative signals as the stock is now trading below the 20 day and 50 day SMA. Momentum readings like the 14-week RSI too are in decline mode and not oversold, which implies potential for more downsides. We therefore expect the stock to correct further in the coming sessions. Sell between the 307-312 levels. CMP is 309.5. Stop loss is at 327 while downside target is at 285.
(Subash Gangadharan, Senior Technical and Derivative Analyst, HDFC Securities. The stock recommendations in this story are by the respective research analysts and brokerage firms. FinancialExpress.com does not bear any responsibility for their investment advice. Capital markets investments are subject to rules and regulations. Please consult your investment advisor before investing.)
猜你喜欢
- Paytm share price jumps 2% despite Q1 net loss widening to Rs 645 crore; should you buy, hold or sell-
- Over 12 listed firms under Sebi’s lens for accounting spinoffs
- Supporting regulatory framework needed to harness benefits of AI- RBI DG
- BPCL, Future Consumer, JK Cement among 143 BSE stocks to hit 52-week lows; 27 scrips at new highs
- Big banner films could see box office pickings top Rupees 13K crore
- Suzlon charts a strong path post debt restructuring
- BoI offers 7
- Oppo Reno 7 5G, Reno 7 Pro 5G launched- Specs, features, India price and everything to know
- s, especially those with taste changes or dietary limits, to stick with the treatment. In a nutshell, BDENZA ORAL SOLUTION is a simpler, more patient-friendly way to tackle prostate cancer. It can help improving the patient compliance to a great extent,” Dr. Aravind Badiger Director, Technical Formulation said in a statement.
BDENZA ORAL SOLUTION represents a significant advancement in prostate cancer therapy, offering relief and hope to millions of patients worldwide.
“BDENZA represents a paradigm shift in prostate cancer therapy. Its introduction aligns with our relentless pursuit to provide accessible and patient-centric healthcare solutions. This first-of-its-kind oral solution that addresses the challenges faced by many patients, offering convenience, reduced side effects, and a palatable sugar-free taste and affordability,” Raheel Shah, BDR Group Director (Business Development) said in a statement.